STAGE III CUTANEOUS MELANOMA AJCC V7
Clinical trials for STAGE III CUTANEOUS MELANOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III CUTANEOUS MELANOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE III CUTANEOUS MELANOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Drug attack on tough melanoma shows promise in early trial
Disease control OngoingThis early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy) and ibrutinib (a targeted therapy)—in 20 people with advanced melanoma that could not be surgically removed. The main goal was to find the safest dose of ibrutinib when used with pembrolizum…
Matched conditions: STAGE III CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Triple threat: new combo therapy targets tough melanoma
Disease control OngoingThis study tests two different three-drug combinations in people with advanced melanoma (skin cancer that has spread or can't be removed). The drugs include an immunotherapy (nivolumab) plus targeted therapies that block cancer growth signals. The goal is to see if these combinat…
Matched conditions: STAGE III CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC